| Pharmacovigilance, risks and adverse effects of self-medication JL Montastruc, E Bondon-Guitton, D Abadie, I Lacroix, A Berreni, ... Therapies 71 (2), 257-262, 2016 | 148 | 2016 |
| Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017 F Montastruc, SY Loo, C Renoux Jama 320 (20), 2149-2151, 2018 | 119 | 2018 |
| Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns A Touafchia, H Bagheri, D Carrié, G Durrieu, A Sommet, L Chouchana, ... Clinical Microbiology and Infection 27 (5), 791. e5-791. e8, 2021 | 118 | 2021 |
| Serotonin syndrome: analysis of cases registered in the French pharmacovigilance database D Abadie, V Rousseau, S Logerot, J Cottin, JL Montastruc, F Montastruc Journal of clinical psychopharmacology 35 (4), 382-388, 2015 | 101 | 2015 |
| Potentially inappropriate medication use among patients with Alzheimer disease in the REAL. FR cohort: be aware of atropinic and benzodiazepine drugs! F Montastruc, V Gardette, C Cantet, A Piau, M Lapeyre-Mestre, B Vellas, ... European journal of clinical pharmacology 69, 1589-1597, 2013 | 100 | 2013 |
| What is pharmacoepidemiology? Definition, methods, interest and clinical applications JL Montastruc, J Benevent, F Montastruc, H Bagheri, F Despas, ... Therapies 74 (2), 169-174, 2019 | 97 | 2019 |
| Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses G Moulis, A Sommet, J Bene, F Montastruc, L Sailler, JL Montastruc, ... PLoS One 7 (11), e48991, 2012 | 92 | 2012 |
| Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database A Revet, F Montastruc, A Roussin, JP Raynaud, M Lapeyre-Mestre, ... BMC psychiatry 20, 1-13, 2020 | 87 | 2020 |
| Hepatic disorders with the use of remdesivir for coronavirus 2019 F Montastruc, S Thuriot, G Durrieu Clinical Gastroenterology and Hepatology 18 (12), 2835-2836, 2020 | 80 | 2020 |
| Adverse drug reactions to self‐medication: a study in a pharmacovigilance database A Berreni, F Montastruc, E Bondon‐Guitton, V Rousseau, D Abadie, ... Fundamental & clinical pharmacology 29 (5), 517-520, 2015 | 70 | 2015 |
| Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: a systematic review and meta-analysis G Moulis, A Audemard-Verger, L Arnaud, C Luxembourger, F Montastruc, ... Autoimmunity reviews 15 (3), 203-209, 2016 | 67 | 2016 |
| Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: a pharmacoepidemiological-pharmacodynamic study in VigiBase F Montastruc, A Palmaro, H Bagheri, L Schmitt, JL Montastruc, ... European Neuropsychopharmacology 25 (10), 1556-1565, 2015 | 66 | 2015 |
| Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study S de Germay, H Bagheri, F Despas, V Rousseau, F Montastruc Rheumatology 59 (9), 2360-2367, 2020 | 60 | 2020 |
| Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database JL Montastruc, M Lafaurie, C de Canecaude, G Durrieu, A Sommet, ... British journal of clinical pharmacology 87 (11), 4334-4340, 2021 | 58 | 2021 |
| Serious central nervous system side effects of cephalosporins: a national analysis of serious reports registered in the French Pharmacovigilance Database C Lacroix, F Kheloufi, F Montastruc, Y Bennis, V Pizzoglio, J Micallef Journal of the Neurological Sciences 398, 196-201, 2019 | 58 | 2019 |
| The importance of drug–drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France F Montastruc, A Sommet, E Bondon-Guitton, G Durrieu, E Bui, H Bagheri, ... European journal of clinical pharmacology 68, 767-775, 2012 | 57 | 2012 |
| Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study D Abrahami, A Douros, H Yin, HY Oriana, JL Faillie, F Montastruc, ... bmj 363, 2018 | 56 | 2018 |
| A comparative study of QT prolongation with serotonin reuptake inhibitors A Ojero-Senard, J Benevent, E Bondon-Guitton, G Durrieu, L Chebane, ... Psychopharmacology 234, 3075-3081, 2017 | 56 | 2017 |
| Exposure to atropinic drugs and frailty status F Moulis, G Moulis, L Balardy, S Gérard, F Montastruc, S Sourdet, ... Journal of the American Medical Directors Association 16 (3), 253-257, 2015 | 56 | 2015 |
| Psychiatric disorders and hydroxychloroquine for coronavirus disease 2019 (COVID-19): a VigiBase study P Garcia, A Revet, A Yrondi, V Rousseau, Y Degboe, F Montastruc Drug Safety 43, 1315-1322, 2020 | 48 | 2020 |
Lapeyre-Mestre MaryseUT3 Professor, CIC (Inserm/CHU de Toulouse/UT3), CEIP-A (CHU de Toulouse)在 univ-tlse3.fr 的电子邮件经过验证
